SANUWAVE Health Reports Q1 2026 Results: Net Loss Significantly Reduced, Reiterates Full-Year Guidance
SNWV is trading near its 52-week low of $15.355 (4.5% above the low) on elevated volume (1.9× avg).
Summary
SANUWAVE Health announced Q1 2026 financial results, highlighting a substantial reduction in net loss and positive operational trends in consumables, alongside reiterated full-year revenue guidance.
Key Events · Earnings and Guidance · SNWV
-
Q1 2026 Financial Results
Revenue for Q1 2026 was $9.6 million, a 3.1% increase from $9.3 million in Q1 2025. Gross margin decreased slightly to 77.3% from 79.0%.
-
Significant Net Loss Reduction
Net loss for Q1 2026 was $1.4 million, a substantial improvement from a $6.1 million net loss in Q1 2025, primarily due to the absence of a $4.9 million non-cash derivative liability loss from the prior year.
-
Operational Strength in Consumables
Ultramist® consumables revenue increased by 15.0% year-over-year to $6.7 million, and unit volumes for consumables set a new all-time record, indicating increased utilization.
-
CEO Optimism on Market Recovery
CEO Morgan Frank noted that a market recovery appears to have begun in February, with increasing optimism and a robust pipeline for the remainder of 2026.
Analysis · SNWV · Industrial Applications And Services
SANUWAVE Health reported a significant reduction in its net loss for Q1 2026, improving to $1.4 million from $6.1 million in the prior year, largely due to the absence of a non-cash derivative liability loss. While operating income swung to a loss, the company achieved modest revenue growth and saw a 15% increase in Ultramist® consumables revenue, with unit volumes setting a new all-time record. The CEO expressed optimism about a market recovery beginning in February and reiterated positive full-year revenue guidance, which is a crucial signal for investors, especially with the stock trading near its 52-week low.
At the time of this filing, SNWV was trading at $16.04 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $137.9M. The 52-week trading range was $15.36 to $46.59. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.